UY34842A - Formulaciones estabilizadas que contienen anticuerpos anti-dll4 - Google Patents

Formulaciones estabilizadas que contienen anticuerpos anti-dll4

Info

Publication number
UY34842A
UY34842A UY0001034842A UY34842A UY34842A UY 34842 A UY34842 A UY 34842A UY 0001034842 A UY0001034842 A UY 0001034842A UY 34842 A UY34842 A UY 34842A UY 34842 A UY34842 A UY 34842A
Authority
UY
Uruguay
Prior art keywords
formulations containing
containing anti
dll4 antibodies
stabilized formulations
stabilized
Prior art date
Application number
UY0001034842A
Other languages
English (en)
Inventor
Walsh Scott
Dix Daniel
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48670784&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY34842(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of UY34842A publication Critical patent/UY34842A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)

Abstract

La presente invención proporciona formulaciones farmacéuticas que comprenden un anticuerpo que se u ne específicamente a ligando tipo delta humano 4 (Dll4). Las formulaciones pueden contener, además de un anticuerpo anti-Dll4, un amortiguador de fo sfato, un cosolvente orgánico, un disacárido y una sal. Las formulaciones farmacéuticas de la prese nte invención conservan un grado sustancial de es tabilidad del anticuerpo después de almacenamiento durante varios meses y después de ser sometidas a estrés térmico y otros estreses.
UY0001034842A 2012-05-31 2013-05-31 Formulaciones estabilizadas que contienen anticuerpos anti-dll4 UY34842A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261653478P 2012-05-31 2012-05-31

Publications (1)

Publication Number Publication Date
UY34842A true UY34842A (es) 2013-12-31

Family

ID=48670784

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001034842A UY34842A (es) 2012-05-31 2013-05-31 Formulaciones estabilizadas que contienen anticuerpos anti-dll4

Country Status (29)

Country Link
US (1) US9675692B2 (es)
EP (1) EP2854849B1 (es)
JP (1) JP6144758B2 (es)
KR (1) KR20150033615A (es)
CN (1) CN104349791A (es)
AR (1) AR092325A1 (es)
AU (1) AU2013267301B2 (es)
BR (1) BR112014028997A2 (es)
CA (1) CA2872275C (es)
CL (1) CL2014003237A1 (es)
CO (1) CO7151478A2 (es)
DK (1) DK2854849T3 (es)
EA (1) EA029779B1 (es)
ES (1) ES2668900T3 (es)
HK (1) HK1207305A1 (es)
IL (1) IL235468A0 (es)
LT (1) LT2854849T (es)
MA (1) MA37645B1 (es)
MX (1) MX357146B (es)
NO (1) NO2887943T3 (es)
NZ (1) NZ702288A (es)
PH (1) PH12014502429A1 (es)
PL (1) PL2854849T3 (es)
PT (1) PT2854849T (es)
SG (1) SG11201407171XA (es)
SI (1) SI2854849T1 (es)
TW (1) TWI609696B (es)
UY (1) UY34842A (es)
WO (1) WO2013181486A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE029661T2 (en) 2009-10-16 2017-03-28 Oncomed Pharm Inc A therapeutic combination and use of DLL4 antagonist antibodies and antihypertensive agents
ES2707580T3 (es) 2011-09-23 2019-04-04 Oncomed Pharm Inc Agentes de unión a VEGF/DLL4 y usos de los mismos
JP6827415B2 (ja) 2014-10-31 2021-02-10 メレオ バイオファーマ ５ インコーポレイテッド 疾患の処置のための併用療法
WO2016080367A1 (ja) * 2014-11-18 2016-05-26 塩野義製薬株式会社 安定化されたペプチド組成物
EP3353204B1 (en) 2015-09-23 2023-10-18 Mereo BioPharma 5, Inc. Bi-specific anti-vegf/dll4 antibody for use in treating platinum-resistant ovarian cancer
US20210379186A1 (en) * 2018-04-16 2021-12-09 Merck Patent Gmbh Additives for protein formulations to improve thermal stability
CR20210435A (es) 2019-02-18 2021-09-20 Lilly Co Eli Formulación de anticuerpos terapéuticos
KR20230035595A (ko) * 2020-07-08 2023-03-14 리제너론 파아마슈티컬스, 인크. 항-ctla-4 항체를 함유하는 안정화된 제형

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0747045B2 (ja) 1986-10-15 1995-05-24 株式会社大協精工 積層した注射器用滑栓
US5016784A (en) 1990-02-15 1991-05-21 Dexus Research Inc. Applicator for highly reactive materials
AU2309692A (en) 1991-07-03 1993-02-11 Cryolife, Inc. Method for stabilization of biomaterials
JP3100727B2 (ja) 1992-01-23 2000-10-23 株式会社大協精工 変性ポリシロキサン組成物及び該組成物を被覆した衛生ゴム製品
NZ255101A (en) 1992-07-24 1997-08-22 Cell Genesys Inc A yeast artificial chromosome (yac) vector containing an hprt minigene expressible in murine stem cells and genetically modified rodent therefor
JP3172057B2 (ja) 1995-04-05 2001-06-04 株式会社大協精工 ラミネートゴム栓
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
EP0852951A1 (de) 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
US7312196B2 (en) 1997-01-08 2007-12-25 Amylin Pharmaceuticals, Inc. Formulations for amylin agonist peptides
DE69810481T2 (de) 1997-06-13 2003-09-25 Genentech Inc Stabilisierte antikörperformulierung
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
JP3512349B2 (ja) 1999-01-29 2004-03-29 株式会社大協精工 柱状ゴム要素の成形型
US7001892B1 (en) 1999-06-11 2006-02-21 Purdue Research Foundation Pharmaceutical materials and methods for their preparation and use
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
US6629949B1 (en) 2000-05-08 2003-10-07 Sterling Medivations, Inc. Micro infusion drug delivery device
US6659982B2 (en) 2000-05-08 2003-12-09 Sterling Medivations, Inc. Micro infusion drug delivery device
JP5485489B2 (ja) 2000-08-11 2014-05-07 中外製薬株式会社 抗体含有安定化製剤
DE60139944D1 (de) 2000-10-12 2009-10-29 Genentech Inc Niederviskose konzentrierte proteinformulierungen
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
JP2002209975A (ja) 2001-01-19 2002-07-30 Daikyo Seiko Ltd 医薬バイアル用ラミネートゴム栓
US20030113316A1 (en) 2001-07-25 2003-06-19 Kaisheva Elizabet A. Stable lyophilized pharmaceutical formulation of IgG antibodies
EP3192528A1 (en) 2002-02-14 2017-07-19 Chugai Seiyaku Kabushiki Kaisha Formulation of anti-il6r antibody-containing solutions comprising a sugar as a stabilizer
AU2003293543A1 (en) 2002-12-13 2004-07-09 Abgenix, Inc. System and method for stabilizing antibodies with histidine
JP4869064B2 (ja) 2003-04-04 2012-02-01 ジェネンテック， インコーポレイテッド 高濃度抗体及びタンパク質製剤
WO2005072772A1 (en) 2004-01-30 2005-08-11 Suomen Punainen Risti Veripalvelu Pharmaceutical compositions
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
PL1861116T3 (pl) 2005-03-25 2016-02-29 Regeneron Pharma Formulacje antagonistów VEGF
EP3673919A1 (en) 2005-06-14 2020-07-01 Amgen Inc. Self-buffering protein formulations
CN101478949A (zh) 2006-06-16 2009-07-08 瑞泽恩制药公司 适合玻璃体内施用的vegf拮抗剂的制剂
US20100129354A1 (en) 2006-10-27 2010-05-27 Ablynx N.V. Intranasal delivery of polypeptides and proteins
RU2448979C2 (ru) 2006-12-14 2012-04-27 Ридженерон Фармасьютикалз, Инк. Антитела человека к дельта-подобному лиганду-4 человека
EP2403874A1 (en) 2009-03-06 2012-01-11 Genentech, Inc. Antibody formulation
HUE029661T2 (en) * 2009-10-16 2017-03-28 Oncomed Pharm Inc A therapeutic combination and use of DLL4 antagonist antibodies and antihypertensive agents
PT3721904T (pt) 2009-11-20 2021-11-15 Biocon Ltd Formulações de anticorpo t1h
BR112012021941A2 (pt) * 2010-03-02 2022-02-01 Abbvie Inc Proteínas terapêuticas de ligação a dll4
MY158130A (en) * 2010-10-06 2016-08-30 Regeneron Pharma Stabilized formulations containing anti-interleukin-4 receptor )il-4r) antibodies

Also Published As

Publication number Publication date
PT2854849T (pt) 2018-05-09
EP2854849A1 (en) 2015-04-08
AU2013267301A1 (en) 2014-12-18
DK2854849T3 (en) 2018-04-30
MA37645A2 (fr) 2016-08-31
HK1207305A1 (en) 2016-01-29
SG11201407171XA (en) 2014-11-27
JP2015520173A (ja) 2015-07-16
IL235468A0 (en) 2014-12-31
CO7151478A2 (es) 2014-12-29
CA2872275A1 (en) 2013-12-05
NZ702288A (en) 2016-12-23
PL2854849T3 (pl) 2018-07-31
ES2668900T3 (es) 2018-05-23
US20130323260A1 (en) 2013-12-05
TW201400130A (zh) 2014-01-01
CL2014003237A1 (es) 2015-07-10
TWI609696B (zh) 2018-01-01
AU2013267301B2 (en) 2018-02-08
US9675692B2 (en) 2017-06-13
MX357146B (es) 2018-06-28
CA2872275C (en) 2021-05-18
EA029779B1 (ru) 2018-05-31
KR20150033615A (ko) 2015-04-01
JP6144758B2 (ja) 2017-06-07
EP2854849B1 (en) 2018-02-28
MA37645A3 (fr) 2017-07-31
SI2854849T1 (en) 2018-05-31
MX2014014363A (es) 2015-02-05
PH12014502429B1 (en) 2015-01-12
LT2854849T (lt) 2018-05-10
BR112014028997A2 (pt) 2017-07-25
EA201492186A1 (ru) 2015-08-31
MA37645B1 (fr) 2018-10-31
PH12014502429A1 (en) 2015-01-12
WO2013181486A1 (en) 2013-12-05
NO2887943T3 (es) 2018-05-05
AR092325A1 (es) 2015-04-15
CN104349791A (zh) 2015-02-11

Similar Documents

Publication Publication Date Title
UY34587A (es) Formulaciones estabilizadas que contienen anticuerpos antiang2
UY34885A (es) Proteínas de unión anti-mesotelina
EA201991715A1 (ru) Композиции, содержащие антитело к pdl1
UY34228A (es) Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9
UY34842A (es) Formulaciones estabilizadas que contienen anticuerpos anti-dll4
IL240754A0 (en) Low concentration antibody compositions
CR20150048A (es) Anticuerpos e inmunoconjugados anti-cd22
EA201491811A1 (ru) АНТИ-LgR5 АНТИТЕЛА И ИММУНОКОНЪЮГАТЫ
EA201590993A1 (ru) Гетеродимерные иммуноглобулины
UY4230Q (es) Bocadillo retorcido para mascota
CR20150046A (es) Anticuerpos anti-cd79b e inmunoconjugados
EA201591750A1 (ru) Антитела против b7-h4 и иммуноконъюгаты
UY34404A (es) Anticuerpo estable unido a múltiples antígenos
EA201401077A1 (ru) Биспецифические антитела к человеческому tweak и человеческому il17 и их применения
UY34779A (es) Anticuerpos anti-il-23 y composiciones farmacéuticas que los contienen
CL2011000481S1 (es) Aplicador para cuidado oral.
UY34581A (es) Dispositivo de inhalación para fármacos en polvo
UY34582A (es) Anticuerpos anti-cxcr3
UY34730A (es) Formulaciones farmacéuticas que comprenden antagonistas de ccr3
UY34142A (es) Composiciones que contienen sal de colina para limpieza
CL2014001862A1 (es) Compuestos derivados de morofolinilo sustituido, útiles como inhibidores de mogat-2; composicion farmaceutica que los comprende; uso en el tratamiento de hipertrigliceridemia.
UY34931A (es) ?formulación compuesta para administración oral que comprende metformina y rosuvastatina?.
UY36292A (es) Compuestos de tetrahidroquinolina para su uso como inhibidores de bromodominios
UY34579A (es) Dispositivo de inhalación para fármacos en polvo
CY1118277T1 (el) Σταθερη φαρμακοτεχνικη μορφη πεξιγανανης